Trial Profile
An Prospective, Multicenter, Double-blind, Randomized, Controlled Clinical Study of Nimotuzumab Combined With Paclitaxel and Cisplatin as First-line Treatment of Metastatic Esophageal Squamous Cell Carcinomas
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Aug 2022
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Cisplatin; Paclitaxel
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Biotech Pharmaceutical
- 26 Nov 2015 New trial record